Effects of Telizumab Injection Combined with Albumin Paclitaxel and Carboplatin on Intestinal Flora,SII and PNI in Patients with Advanced NSCLC
Objective:To investigate the effects of telizumab injection combined with albumin paclitaxel and carboplatin on intestinal flora and prognostic nutritional index(PNI)and systemic immune inflammatory index(SII)in patients with advanced non small cell lung cancer(NSCLC).Methods:115 patients with advanced NSCLC who were treated in Nanjing Jiangning Hospital and Zhongda Hospital Affiliated to Southeast University from May 2020 to February 2023 were selected.Patients were divided into control group and study group according to the random number table method,57 cases and 58 cases respectively.Control group was treated with albumin paclitaxel and carboplatin,and study group was treated with tirelizumab injection on the basis of control group.The objective response rate(ORR),disease control rate(DCR),serum tumor markers[cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],intestinal flora(bifidobacterium,lactobacillus,Enterococcus),SII and PNI were compared between two groups,and the incidence of adverse reactions during treatment was observed.Results:The ORR(44.83％)and DCR(77.59％)in study group were higher than those in control group(24.56％,50.88％)(P＜0.05).Compared with control group after treatment,CYFRA21-1,CEA,CA125,Enterococcus and SII in study group were lower,and bifidobacterium,lactobacillus and PNI were higher(P＜0.05).There was no difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion:Tirelizumab injection combined with albumin paclitaxel and carboplatin in the treatment of patients with advanced NSCLC,which can improve clinical efficacy and improve SII,PNI and intestinal flora.
Teralizumab InjectionAlbumin paclitaxelCarboplatinAdvancedNon small cell lung cancerIntestinal floraSIIPNI
NETL
NSTL
万方数据
维普
